# CPG 7909 in Patients With Cutaneous T-Cell Lymphoma

> **NCT00043420** · PHASE1,PHASE2 · COMPLETED · sponsor: **Pfizer** · enrollment: 42 (actual)

## Conditions studied

- Lymphoma, T-Cell, Cutaneous

## Interventions

- **DRUG:** PF-3512676
- **DRUG:** PF-3512676
- **DRUG:** PF-3512676
- **DRUG:** PF-3512676
- **DRUG:** PF-3512676
- **DRUG:** PF-3512676
- **DRUG:** PF-3512676
- **DRUG:** PF-3512676

## Key facts

- **NCT ID:** NCT00043420
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-01
- **Primary completion:** 2007-03
- **Final completion:** 2007-03
- **Target enrollment:** 42 (ACTUAL)
- **Last updated:** 2009-02-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00043420

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00043420, "CPG 7909 in Patients With Cutaneous T-Cell Lymphoma". Retrieved via AI Analytics 2026-07-18 from https://api.ai-analytics.org/clinical/NCT00043420. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*